No significant difference was found between other treatments .
Conclusion Compared with antimuscarinic drugs , PTENS was associated with significant better efficacy considering MVV , but more constipation events in de novo OAB children .
Antimuscarinic drugs showed remarkably better efficacy considering MVV and comparable safety profile compared with urotherapy .
Objective To compare these managements focusing on the efficacy and safety to treat overactive bladder ( OAB ) in children through network meta- analysis ( NMA ) .
Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.
BACKGROUND Solifenacin , an effective , well-tolerated treatment for adult overactive bladder ( OAB ) symptoms , has not been evaluated in placebo-controlled paediatric clinical trials . OBJECTIVES To evaluate the efficacy and safety of once-daily oral solifenacin suspension in OAB patients aged 5-<12 yr ( children ) and 12-<18 yr ( adolescents ) . DESIGN , SETTING , AND PARTICIPANTS The study involved a 4-wk urotherapy run-in followed by 1:1 r and omisation to 12-wk double-blind solifenacin or placebo treatment alongside urotherapy . INTERVENTION Solifenacin paediatric equivalent doses ( PEDs ) of adult doses : 2.5 mg , 5 mg , 7.5 mg , and 10 mg . The starting dose was PED 5 mg ; all patients were titrated to an optimum dose at 3-wk intervals over 9 wk , result ing in ≥3 wk at the optimum dose before end of treatment ( EoT ) . OUTCOME MEASUREMENTS AND STATISTICS Superiority of solifenacin versus placebo in change from baseline to EoT for mean volume voided/micturition ( MVV , primary endpoint ) ; daytime maximum volume voided/micturition ( DMaxVV ) ; incontinence episodes ( mean/24h ) ; mean number of incontinence-free days or nights/7 d ; micturition frequency ; and Micturition frequency adjusted for baseline total voided volume ( VTB ) as an exploratory parameter ) . Efficacy parameters were analysed using analysis of covariance . Safety parameters ( treatment-emergent adverse events , serious adverse events , laboratory variables , vital signs , electrocardiogram , postvoid residual volume ) are summarised using descriptive statistics . RESULTS AND LIMITATIONS In children , solifenacin was superior to placebo in terms of the change from baseline to EoT for MVV  ( solifenacin-placebo difference 12.1ml , 95 % confidence interval [ CI ] 0.2 - 24.0 ; p=0.046 ) , DMaxVV ( difference in adjusted mean change from baseline for solifenacin-placebo 31.9ml , 95 % CI 4.3 - 59.5 ; p=0.024 ) , VTB-adjusted micturition frequency ( p=0.028 ) . Other endpoints were not significantly different . Solifenacin was well tolerated . For adolescents , it was not possible to draw firm efficacy conclusions because of the low numbers recruited . CONCLUSIONS Once-daily solifenacin oral suspension in children with OAB was superior to placebo for MVV ( primary efficacy endpoint ) and was well tolerated . PATIENT SUMMARY In this 12-wk study , a once-daily oral suspension of solifenacin in children aged 5-<12 yr with overactive bladder was superior to placebo in increasing mean volume voided/micturition , the primary efficacy variable in the study . Solifenacin was well tolerated , with a low incidence of dry mouth and constipation . This study is registered at Clinical Trials.gov as NCT01565707
No significant difference was found between other treatments .
Conclusion Compared with antimuscarinic drugs , PTENS was associated with significant better efficacy considering MVV , but more constipation events in de novo OAB children .
Antimuscarinic drugs showed remarkably better efficacy considering MVV and comparable safety profile compared with urotherapy .
Objective To compare these managements focusing on the efficacy and safety to treat overactive bladder ( OAB ) in children through network meta- analysis ( NMA ) .